BR112019019367A2 - construções de terapia genética e métodos para tratamento de perda auditiva - Google Patents
construções de terapia genética e métodos para tratamento de perda auditiva Download PDFInfo
- Publication number
- BR112019019367A2 BR112019019367A2 BR112019019367A BR112019019367A BR112019019367A2 BR 112019019367 A2 BR112019019367 A2 BR 112019019367A2 BR 112019019367 A BR112019019367 A BR 112019019367A BR 112019019367 A BR112019019367 A BR 112019019367A BR 112019019367 A2 BR112019019367 A2 BR 112019019367A2
- Authority
- BR
- Brazil
- Prior art keywords
- nucleic acid
- fact
- tmprss3
- promoters
- hearing loss
- Prior art date
Links
- 206010011878 Deafness Diseases 0.000 title claims abstract description 171
- 208000016354 hearing loss disease Diseases 0.000 title claims abstract description 171
- 230000010370 hearing loss Effects 0.000 title claims abstract description 143
- 231100000888 hearing loss Toxicity 0.000 title claims abstract description 143
- 238000000034 method Methods 0.000 title claims abstract description 39
- 238000001415 gene therapy Methods 0.000 title description 25
- 238000010276 construction Methods 0.000 title description 2
- 230000035772 mutation Effects 0.000 claims abstract description 94
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 69
- 210000003027 ear inner Anatomy 0.000 claims abstract description 37
- 239000013603 viral vector Substances 0.000 claims abstract description 29
- 238000011282 treatment Methods 0.000 claims abstract description 13
- 230000002265 prevention Effects 0.000 claims abstract description 7
- 101000798700 Homo sapiens Transmembrane protease serine 3 Proteins 0.000 claims description 93
- 210000004027 cell Anatomy 0.000 claims description 70
- 102100032454 Transmembrane protease serine 3 Human genes 0.000 claims description 69
- 101000798702 Homo sapiens Transmembrane protease serine 4 Proteins 0.000 claims description 68
- 150000007523 nucleic acids Chemical group 0.000 claims description 52
- 241000702423 Adeno-associated virus - 2 Species 0.000 claims description 41
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 35
- 230000002068 genetic effect Effects 0.000 claims description 31
- 239000013604 expression vector Substances 0.000 claims description 26
- 241001634120 Adeno-associated virus - 5 Species 0.000 claims description 16
- 241000972680 Adeno-associated virus - 6 Species 0.000 claims description 16
- 241001164823 Adeno-associated virus - 7 Species 0.000 claims description 16
- 241001164825 Adeno-associated virus - 8 Species 0.000 claims description 16
- 108020004707 nucleic acids Proteins 0.000 claims description 16
- 102000039446 nucleic acids Human genes 0.000 claims description 16
- 241000701024 Human betaherpesvirus 5 Species 0.000 claims description 12
- 238000002347 injection Methods 0.000 claims description 10
- 239000007924 injection Substances 0.000 claims description 10
- 241001655883 Adeno-associated virus - 1 Species 0.000 claims description 8
- 241000202702 Adeno-associated virus - 3 Species 0.000 claims description 8
- 241000580270 Adeno-associated virus - 4 Species 0.000 claims description 8
- 241000287828 Gallus gallus Species 0.000 claims description 7
- 210000001062 endolymphatic sac Anatomy 0.000 claims description 7
- 239000008194 pharmaceutical composition Substances 0.000 claims description 7
- 108010085238 Actins Proteins 0.000 claims description 6
- 241000701022 Cytomegalovirus Species 0.000 claims description 6
- 210000004263 induced pluripotent stem cell Anatomy 0.000 claims description 6
- 239000012528 membrane Substances 0.000 claims description 6
- 210000004379 membrane Anatomy 0.000 claims description 6
- 101150016977 pou4f3 gene Proteins 0.000 claims description 6
- 239000003814 drug Substances 0.000 claims description 5
- 210000000130 stem cell Anatomy 0.000 claims description 5
- 210000000262 cochlear duct Anatomy 0.000 claims description 3
- 229940079593 drug Drugs 0.000 claims description 3
- 102000007469 Actins Human genes 0.000 claims 4
- 230000009261 transgenic effect Effects 0.000 claims 1
- 210000002768 hair cell Anatomy 0.000 abstract description 83
- 230000004083 survival effect Effects 0.000 abstract description 16
- 230000000694 effects Effects 0.000 abstract description 8
- 239000000203 mixture Substances 0.000 abstract description 8
- 239000013598 vector Substances 0.000 description 70
- 241000699670 Mus sp. Species 0.000 description 46
- 101100260870 Mus musculus Tmprss3 gene Proteins 0.000 description 31
- 238000010172 mouse model Methods 0.000 description 31
- 241000699666 Mus <mouse, genus> Species 0.000 description 22
- 231100000895 deafness Toxicity 0.000 description 21
- 241000282412 Homo Species 0.000 description 20
- 230000014509 gene expression Effects 0.000 description 19
- 239000007943 implant Substances 0.000 description 19
- 230000000750 progressive effect Effects 0.000 description 18
- 241001465754 Metazoa Species 0.000 description 17
- 239000005090 green fluorescent protein Substances 0.000 description 17
- 206010010356 Congenital anomaly Diseases 0.000 description 16
- 210000001323 spiral ganglion Anatomy 0.000 description 16
- 230000006870 function Effects 0.000 description 15
- 210000003477 cochlea Anatomy 0.000 description 14
- 102000004169 proteins and genes Human genes 0.000 description 14
- 108091033409 CRISPR Proteins 0.000 description 13
- 238000012360 testing method Methods 0.000 description 13
- 101001043326 Homo sapiens Lipoxygenase homology domain-containing protein 1 Proteins 0.000 description 12
- 208000036201 autosomal recessive hearing loss Diseases 0.000 description 12
- 238000011161 development Methods 0.000 description 12
- 230000018109 developmental process Effects 0.000 description 12
- 102100021959 Lipoxygenase homology domain-containing protein 1 Human genes 0.000 description 11
- 239000013543 active substance Substances 0.000 description 11
- 230000003915 cell function Effects 0.000 description 10
- 102000045778 human TMPRSS3 Human genes 0.000 description 10
- 230000007850 degeneration Effects 0.000 description 9
- 238000011084 recovery Methods 0.000 description 9
- 230000004044 response Effects 0.000 description 9
- 210000000349 chromosome Anatomy 0.000 description 8
- 239000002299 complementary DNA Substances 0.000 description 8
- 238000002560 therapeutic procedure Methods 0.000 description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 239000013607 AAV vector Substances 0.000 description 6
- 201000004384 Alopecia Diseases 0.000 description 6
- 238000010354 CRISPR gene editing Methods 0.000 description 6
- 206010011891 Deafness neurosensory Diseases 0.000 description 6
- 208000009966 Sensorineural Hearing Loss Diseases 0.000 description 6
- 230000001413 cellular effect Effects 0.000 description 6
- 210000005069 ears Anatomy 0.000 description 6
- 210000002950 fibroblast Anatomy 0.000 description 6
- 230000003676 hair loss Effects 0.000 description 6
- 230000008140 language development Effects 0.000 description 6
- 201000006790 nonsyndromic deafness Diseases 0.000 description 6
- 231100000879 sensorineural hearing loss Toxicity 0.000 description 6
- 208000023573 sensorineural hearing loss disease Diseases 0.000 description 6
- 238000001890 transfection Methods 0.000 description 6
- 102100022509 Cadherin-23 Human genes 0.000 description 5
- 101000899442 Homo sapiens Cadherin-23 Proteins 0.000 description 5
- 101100343697 Homo sapiens LOXHD1 gene Proteins 0.000 description 5
- 241001362551 Samba Species 0.000 description 5
- 241000700605 Viruses Species 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 230000006378 damage Effects 0.000 description 5
- 230000002950 deficient Effects 0.000 description 5
- 230000002939 deleterious effect Effects 0.000 description 5
- 230000001419 dependent effect Effects 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 210000000883 ear external Anatomy 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- -1 ECH0S1 Proteins 0.000 description 4
- 108020005004 Guide RNA Proteins 0.000 description 4
- 208000009889 Herpes Simplex Diseases 0.000 description 4
- 108700019146 Transgenes Proteins 0.000 description 4
- 206010046865 Vaccinia virus infection Diseases 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 230000003111 delayed effect Effects 0.000 description 4
- 238000009826 distribution Methods 0.000 description 4
- 230000004064 dysfunction Effects 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 238000011813 knockout mouse model Methods 0.000 description 4
- 230000007774 longterm Effects 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 230000002797 proteolythic effect Effects 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 102220015155 rs181949335 Human genes 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 238000011830 transgenic mouse model Methods 0.000 description 4
- 208000007089 vaccinia Diseases 0.000 description 4
- 230000001720 vestibular Effects 0.000 description 4
- 241001406376 Betasatellite Species 0.000 description 3
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 3
- 206010064571 Gene mutation Diseases 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 101000801040 Homo sapiens Transmembrane channel-like protein 1 Proteins 0.000 description 3
- 208000026350 Inborn Genetic disease Diseases 0.000 description 3
- 102000035195 Peptidases Human genes 0.000 description 3
- 108091005804 Peptidases Proteins 0.000 description 3
- 239000004365 Protease Substances 0.000 description 3
- 101150065274 Tmc gene Proteins 0.000 description 3
- 102100033690 Transmembrane channel-like protein 1 Human genes 0.000 description 3
- 108090000631 Trypsin Proteins 0.000 description 3
- 102000004142 Trypsin Human genes 0.000 description 3
- 230000005856 abnormality Effects 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 210000000133 brain stem Anatomy 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 235000013330 chicken meat Nutrition 0.000 description 3
- 238000002648 combination therapy Methods 0.000 description 3
- 230000007812 deficiency Effects 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 239000012091 fetal bovine serum Substances 0.000 description 3
- 208000016361 genetic disease Diseases 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 238000003780 insertion Methods 0.000 description 3
- 230000037431 insertion Effects 0.000 description 3
- 230000035800 maturation Effects 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 230000002028 premature Effects 0.000 description 3
- 238000009118 salvage therapy Methods 0.000 description 3
- 210000002480 semicircular canal Anatomy 0.000 description 3
- 238000007619 statistical method Methods 0.000 description 3
- 210000003582 temporal bone Anatomy 0.000 description 3
- 238000010361 transduction Methods 0.000 description 3
- 230000026683 transduction Effects 0.000 description 3
- 230000010415 tropism Effects 0.000 description 3
- 239000012588 trypsin Substances 0.000 description 3
- 230000003612 virological effect Effects 0.000 description 3
- 102100022900 Actin, cytoplasmic 1 Human genes 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 241000700198 Cavia Species 0.000 description 2
- 208000000781 Conductive Hearing Loss Diseases 0.000 description 2
- 206010010280 Conductive deafness Diseases 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- 241000702421 Dependoparvovirus Species 0.000 description 2
- 108090000128 Lipoxygenases Proteins 0.000 description 2
- 102000003820 Lipoxygenases Human genes 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 241000699660 Mus musculus Species 0.000 description 2
- 206010033109 Ototoxicity Diseases 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 102000012479 Serine Proteases Human genes 0.000 description 2
- 108010022999 Serine Proteases Proteins 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 150000001413 amino acids Chemical group 0.000 description 2
- 238000000540 analysis of variance Methods 0.000 description 2
- 201000006140 autosomal recessive nonsyndromic deafness 77 Diseases 0.000 description 2
- 208000033022 autosomal recessive nonsyndromic hearing loss 77 Diseases 0.000 description 2
- 230000002146 bilateral effect Effects 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 230000010336 brain pathway Effects 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- 208000023563 conductive hearing loss disease Diseases 0.000 description 2
- 238000012790 confirmation Methods 0.000 description 2
- 238000005520 cutting process Methods 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 210000003060 endolymph Anatomy 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 230000030414 genetic transfer Effects 0.000 description 2
- 238000003364 immunohistochemistry Methods 0.000 description 2
- 238000000126 in silico method Methods 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 208000012496 juvenile nasopharyngeal angiofibroma Diseases 0.000 description 2
- 230000036244 malformation Effects 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 238000007479 molecular analysis Methods 0.000 description 2
- 210000002569 neuron Anatomy 0.000 description 2
- 231100000989 no adverse effect Toxicity 0.000 description 2
- 210000002985 organ of corti Anatomy 0.000 description 2
- 210000004789 organ system Anatomy 0.000 description 2
- 231100000262 ototoxicity Toxicity 0.000 description 2
- 210000004049 perilymph Anatomy 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 102220054698 rs727503146 Human genes 0.000 description 2
- 102220054522 rs727503493 Human genes 0.000 description 2
- 210000003491 skin Anatomy 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 238000012549 training Methods 0.000 description 2
- 238000013519 translation Methods 0.000 description 2
- 241000701161 unidentified adenovirus Species 0.000 description 2
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 1
- 102100030374 Actin, cytoplasmic 2 Human genes 0.000 description 1
- 239000012103 Alexa Fluor 488 Substances 0.000 description 1
- 101710092462 Alpha-hemolysin Proteins 0.000 description 1
- 102100040191 Alpha-tectorin Human genes 0.000 description 1
- 101710197219 Alpha-toxin Proteins 0.000 description 1
- 229940088872 Apoptosis inhibitor Drugs 0.000 description 1
- 201000004569 Blindness Diseases 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 208000023914 Central Auditory disease Diseases 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 241000700114 Chinchillidae Species 0.000 description 1
- 241001044069 Clarina Species 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 102100037024 E3 ubiquitin-protein ligase XIAP Human genes 0.000 description 1
- 229910052688 Gadolinium Inorganic materials 0.000 description 1
- 102100037156 Gap junction beta-2 protein Human genes 0.000 description 1
- 208000016621 Hearing disease Diseases 0.000 description 1
- 101000773237 Homo sapiens Actin, cytoplasmic 2 Proteins 0.000 description 1
- 101000889766 Homo sapiens Alpha-tectorin Proteins 0.000 description 1
- 101000954092 Homo sapiens Gap junction beta-2 protein Proteins 0.000 description 1
- 101100180047 Homo sapiens ISL1 gene Proteins 0.000 description 1
- 101001134169 Homo sapiens Otoferlin Proteins 0.000 description 1
- 101001072259 Homo sapiens Protocadherin-15 Proteins 0.000 description 1
- 101100260869 Homo sapiens TMPRSS3 gene Proteins 0.000 description 1
- 101000585635 Homo sapiens Unconventional myosin-XV Proteins 0.000 description 1
- 101000666127 Homo sapiens Whirlin Proteins 0.000 description 1
- YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- 241000713666 Lentivirus Species 0.000 description 1
- 241000270322 Lepidosauria Species 0.000 description 1
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 1
- 208000008719 Mixed Conductive-Sensorineural Hearing Loss Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 102100034198 Otoferlin Human genes 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 101710124951 Phospholipase C Proteins 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 102100036382 Protocadherin-15 Human genes 0.000 description 1
- 238000003559 RNA-seq method Methods 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 206010040030 Sensory loss Diseases 0.000 description 1
- 241000700584 Simplexvirus Species 0.000 description 1
- 101150086693 Slc17a8 gene Proteins 0.000 description 1
- 108010004408 TRPP Cation Channels Proteins 0.000 description 1
- 102100029836 Unconventional myosin-XV Human genes 0.000 description 1
- 241000700618 Vaccinia virus Species 0.000 description 1
- 102100038033 Vesicular glutamate transporter 3 Human genes 0.000 description 1
- 102100038102 Whirlin Human genes 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 108700031544 X-Linked Inhibitor of Apoptosis Proteins 0.000 description 1
- 208000019467 X-linked deafness Diseases 0.000 description 1
- NOSIYYJFMPDDSA-UHFFFAOYSA-N acepromazine Chemical compound C1=C(C(C)=O)C=C2N(CCCN(C)C)C3=CC=CC=C3SC2=C1 NOSIYYJFMPDDSA-UHFFFAOYSA-N 0.000 description 1
- 229960005054 acepromazine Drugs 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 238000004026 adhesive bonding Methods 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 239000002776 alpha toxin Substances 0.000 description 1
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 1
- 239000000158 apoptosis inhibitor Substances 0.000 description 1
- 210000003030 auditory receptor cell Anatomy 0.000 description 1
- 201000005823 autosomal dominant nonsyndromic deafness 12 Diseases 0.000 description 1
- 208000034083 autosomal dominant nonsyndromic hearing loss 12 Diseases 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- AIYUHDOJVYHVIT-UHFFFAOYSA-M caesium chloride Chemical compound [Cl-].[Cs+] AIYUHDOJVYHVIT-UHFFFAOYSA-M 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000006727 cell loss Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 210000003710 cerebral cortex Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 210000000860 cochlear nerve Anatomy 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 238000009223 counseling Methods 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000005786 degenerative changes Effects 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 230000036267 drug metabolism Effects 0.000 description 1
- 210000000613 ear canal Anatomy 0.000 description 1
- 210000000959 ear middle Anatomy 0.000 description 1
- 238000001493 electron microscopy Methods 0.000 description 1
- 210000001671 embryonic stem cell Anatomy 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 230000000763 evoking effect Effects 0.000 description 1
- 239000000834 fixative Substances 0.000 description 1
- UIWYJDYFSGRHKR-UHFFFAOYSA-N gadolinium atom Chemical compound [Gd] UIWYJDYFSGRHKR-UHFFFAOYSA-N 0.000 description 1
- 230000009395 genetic defect Effects 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 230000008230 hearing development Effects 0.000 description 1
- 102000055368 human LOXHD1 Human genes 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 238000002991 immunohistochemical analysis Methods 0.000 description 1
- 238000012744 immunostaining Methods 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000007901 in situ hybridization Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 229960003299 ketamine Drugs 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000007257 malfunction Effects 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- AYOOGWWGECJQPI-NSHDSACASA-N n-[(1s)-1-(5-fluoropyrimidin-2-yl)ethyl]-3-(3-propan-2-yloxy-1h-pyrazol-5-yl)imidazo[4,5-b]pyridin-5-amine Chemical compound N1C(OC(C)C)=CC(N2C3=NC(N[C@@H](C)C=4N=CC(F)=CN=4)=CC=C3N=C2)=N1 AYOOGWWGECJQPI-NSHDSACASA-N 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 238000010899 nucleation Methods 0.000 description 1
- 210000004940 nucleus Anatomy 0.000 description 1
- 229920002113 octoxynol Polymers 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 210000001778 pluripotent stem cell Anatomy 0.000 description 1
- 102000054765 polymorphisms of proteins Human genes 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 230000002250 progressing effect Effects 0.000 description 1
- 230000000135 prohibitive effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 230000003362 replicative effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000010255 response to auditory stimulus Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 102220000180 rs121918370 Human genes 0.000 description 1
- 102200098637 rs137852999 Human genes 0.000 description 1
- 102200098636 rs137853000 Human genes 0.000 description 1
- 102220016868 rs188119157 Human genes 0.000 description 1
- 102200098628 rs28939084 Human genes 0.000 description 1
- 102200098632 rs56264519 Human genes 0.000 description 1
- 102220054410 rs727504304 Human genes 0.000 description 1
- 231100000279 safety data Toxicity 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 210000002356 skeleton Anatomy 0.000 description 1
- 230000007958 sleep Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 210000002205 spiral ligament of cochlea Anatomy 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 210000000645 stria vascularis Anatomy 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 101150009136 tlcA gene Proteins 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 238000006276 transfer reaction Methods 0.000 description 1
- 238000013520 translational research Methods 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 208000027491 vestibular disease Diseases 0.000 description 1
- 210000000752 vestibulocochlear nerve Anatomy 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 229940072358 xylocaine Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
- A61K48/0058—Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0275—Genetically modified vertebrates, e.g. transgenic
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0275—Genetically modified vertebrates, e.g. transgenic
- A01K67/0278—Knock-in vertebrates, e.g. humanised vertebrates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0046—Ear
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0696—Artificially induced pluripotent stem cells, e.g. iPS
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/07—Animals genetically altered by homologous recombination
- A01K2217/072—Animals genetically altered by homologous recombination maintaining or altering function, i.e. knock in
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/07—Animals genetically altered by homologous recombination
- A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/105—Murine
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/0306—Animal model for genetic diseases
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14171—Demonstrated in vivo effect
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Wood Science & Technology (AREA)
- Molecular Biology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Environmental Sciences (AREA)
- Virology (AREA)
- Biophysics (AREA)
- Animal Husbandry (AREA)
- Biodiversity & Conservation Biology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Toxicology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Dermatology (AREA)
- Mycology (AREA)
- Developmental Biology & Embryology (AREA)
- Transplantation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762472790P | 2017-03-17 | 2017-03-17 | |
| US201762531522P | 2017-07-12 | 2017-07-12 | |
| PCT/US2018/022873 WO2018170402A1 (en) | 2017-03-17 | 2018-03-16 | Gene therapy constructs and methods for treatment of hearing loss |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112019019367A2 true BR112019019367A2 (pt) | 2020-04-14 |
Family
ID=63522674
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112019019367A BR112019019367A2 (pt) | 2017-03-17 | 2018-03-16 | construções de terapia genética e métodos para tratamento de perda auditiva |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US20200248203A1 (enExample) |
| EP (1) | EP3595634B1 (enExample) |
| JP (1) | JP2020509786A (enExample) |
| KR (1) | KR102752457B1 (enExample) |
| CN (1) | CN110709060A (enExample) |
| BR (1) | BR112019019367A2 (enExample) |
| CA (1) | CA3054941A1 (enExample) |
| ES (1) | ES2982270T3 (enExample) |
| IL (1) | IL268912B2 (enExample) |
| WO (1) | WO2018170402A1 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12391936B2 (en) | 2017-03-17 | 2025-08-19 | Rescue Hearing, Inc. | Gene therapy systems and related methods for treatment of hearing loss |
| US12534739B2 (en) | 2018-10-11 | 2026-01-27 | Decibel Therapeutics, Inc. | AAV1 vectors and uses thereof for treatment of otic indications |
| CN115820654A (zh) * | 2019-08-30 | 2023-03-21 | 深圳华大基因股份有限公司 | Loxhd1基因突变体及其应用 |
| EP4081232A4 (en) * | 2020-02-05 | 2024-02-28 | Rescue Hearing Inc | GENE THERAPY SYSTEMS AND ASSOCIATED METHODS FOR THE TREATMENT OF HEARING LOSS |
| EP4008788A1 (en) * | 2020-12-03 | 2022-06-08 | Medizinische Hochschule Hannover | Lentiviral vector technology for inner ear gene therapy |
| CN113584082B (zh) * | 2021-06-22 | 2023-07-25 | 复旦大学附属眼耳鼻喉科医院 | CRISPR/Cas9基因编辑系统及其在制备治疗遗传性感音神经性聋的药物中的应用 |
| CN113215248B (zh) * | 2021-06-25 | 2022-04-22 | 中国人民解放军空军军医大学 | 一种感音神经性耳聋相关的myo15a基因突变检测试剂盒 |
| CN121568725A (zh) * | 2023-06-15 | 2026-02-24 | 里珍纳龙药品有限公司 | 用于听力病症的基因疗法 |
| CN121674484A (zh) * | 2025-11-14 | 2026-03-17 | 广州派真生物技术有限公司 | 一种高产细胞毒性基因的rAAV质粒系统及应用 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1280923A2 (en) * | 2000-04-28 | 2003-02-05 | Millennium Pharmaceuticals, Inc. | 14094, a human trypsin family member and uses thereof |
| WO2004099779A1 (en) * | 2003-05-05 | 2004-11-18 | Bayer Healthcare Ag | Diagnostics and therapeutics for diseases associated with human transmembrane serine protease 3 (tmprss3) |
| EP1995321A2 (en) * | 2005-08-15 | 2008-11-26 | Genentech, Inc. | Gene disruptions, compositions and methods relating thereto |
| WO2011075838A1 (en) * | 2009-12-21 | 2011-06-30 | Audigen Inc. | Method of treating or preventing hearing loss |
| US20150050354A1 (en) * | 2012-04-02 | 2015-02-19 | Moderna Therapeutics, Inc. | Modified polynucleotides for the treatment of otic diseases and conditions |
| CN116622704A (zh) | 2012-07-25 | 2023-08-22 | 布罗德研究所有限公司 | 可诱导的dna结合蛋白和基因组干扰工具及其应用 |
| WO2015048577A2 (en) | 2013-09-27 | 2015-04-02 | Editas Medicine, Inc. | Crispr-related methods and compositions |
| HUE052676T2 (hu) | 2013-10-11 | 2021-05-28 | Massachusetts Eye & Ear Infirmary | Eljárások õsi vírusszekvenciák elõrejelzésére és alkalmazásaik |
| WO2015175642A2 (en) * | 2014-05-13 | 2015-11-19 | Sangamo Biosciences, Inc. | Methods and compositions for prevention or treatment of a disease |
| EP3212221B1 (en) | 2014-10-29 | 2023-12-06 | Massachusetts Eye & Ear Infirmary | Efficient delivery of therapeutic molecules in vitro and in vivo |
| CA3007476A1 (en) * | 2015-12-11 | 2017-06-15 | Massachusetts Eye And Ear Infirmary | Materials and methods for delivering nucleic acids to cochlear and vestibular cells |
-
2018
- 2018-03-16 EP EP18768248.9A patent/EP3595634B1/en active Active
- 2018-03-16 IL IL268912A patent/IL268912B2/en unknown
- 2018-03-16 WO PCT/US2018/022873 patent/WO2018170402A1/en not_active Ceased
- 2018-03-16 CA CA3054941A patent/CA3054941A1/en active Pending
- 2018-03-16 US US16/488,103 patent/US20200248203A1/en active Pending
- 2018-03-16 CN CN201880028001.3A patent/CN110709060A/zh active Pending
- 2018-03-16 KR KR1020197030012A patent/KR102752457B1/ko active Active
- 2018-03-16 BR BR112019019367A patent/BR112019019367A2/pt unknown
- 2018-03-16 JP JP2020500024A patent/JP2020509786A/ja active Pending
- 2018-03-16 ES ES18768248T patent/ES2982270T3/es active Active
-
2019
- 2019-12-24 US US16/726,495 patent/US20200114023A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| KR102752457B1 (ko) | 2025-01-09 |
| ES2982270T3 (es) | 2024-10-15 |
| EP3595634A1 (en) | 2020-01-22 |
| IL268912B2 (en) | 2024-11-01 |
| JP2020509786A (ja) | 2020-04-02 |
| EP3595634A4 (en) | 2020-11-04 |
| KR20190131052A (ko) | 2019-11-25 |
| CA3054941A1 (en) | 2018-09-20 |
| WO2018170402A1 (en) | 2018-09-20 |
| EP3595634B1 (en) | 2024-03-27 |
| IL268912B1 (en) | 2024-07-01 |
| US20200248203A1 (en) | 2020-08-06 |
| US20200114023A1 (en) | 2020-04-16 |
| IL268912A (en) | 2019-10-31 |
| CN110709060A (zh) | 2020-01-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2982270T3 (es) | Constructos y procedimientos de terapia génica para el tratamiento de la pérdida de audición | |
| Xiao et al. | Rescue of autosomal dominant hearing loss by in vivo delivery of mini dCas13X-derived RNA base editor | |
| György et al. | Gene transfer with AAV9-PHP. B rescues hearing in a mouse model of usher syndrome 3A and transduces hair cells in a non-human primate | |
| Zhang et al. | Preclinical evaluation of the efficacy and safety of AAV1-hOTOF in mice and nonhuman primates | |
| Chang et al. | Virally mediated Kcnq1 gene replacement therapy in the immature scala media restores hearing in a mouse model of human Jervell and Lange‐Nielsen deafness syndrome | |
| CN116236591B (zh) | 用于将核酸递送至耳蜗和前庭细胞的材料和方法 | |
| Grotz et al. | Early disruption of photoreceptor cell architecture and loss of vision in a humanized pig model of usher syndromes | |
| Du et al. | Rescue of auditory function by a single administration of AAV-TMPRSS3 gene therapy in aged mice of human recessive deafness DFNB8 | |
| Cui et al. | A base editor for the long-term restoration of auditory function in mice with recessive profound deafness | |
| Tamura et al. | CRISPR activation rescues abnormalities in SCN2A haploinsufficiency-associated autism spectrum disorder | |
| Dai et al. | AAV-mediated lysophosphatidylcholine acyltransferase 1 (Lpcat1) gene replacement therapy rescues retinal degeneration in rd11 mice | |
| US20230295654A1 (en) | Methods and compositions for treatment of fragile x syndrome | |
| US20260091131A1 (en) | Products and methods for use in treating ndp-related diseases | |
| Duhon et al. | Gene therapy advancements for the treatment of acquired and hereditary hearing loss | |
| US12491223B2 (en) | Method for treating an auditory neuropathy spectrum disorder | |
| Xia et al. | New role of LRP5, associated with nonsyndromic autosomal‐recessive hereditary hearing loss | |
| CN119855907A (zh) | 用于治疗人受试者的非年龄相关性听力损伤的组合物和方法 | |
| CN118215508A (zh) | 编码耳畸蛋白同工型5的双重组aav8载体系统及其用途 | |
| CA3166104A1 (en) | Gene therapy systems and related methods for treatment of hearing loss | |
| US12391936B2 (en) | Gene therapy systems and related methods for treatment of hearing loss | |
| HK40014702A (en) | Gene therapy constructs and methods for treatment of hearing loss | |
| Rieders | Investigating the Dysregulation and Therapeutic Potential of Neuroprotective Stress Response Proteins in Huntington’s Disease |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B350 | Update of information on the portal [chapter 15.35 patent gazette] | ||
| B06W | Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette] |